Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model.

Ward Y, Lake R, Martin PL, Killian K, Salerno P, Wang T, Meltzer P, Merino M, Cheng SY, Santoro M, Garcia-Rostan G, Kelly K.

Oncogene. 2013 May 30;32(22):2726-38. doi: 10.1038/onc.2012.301. Epub 2012 Jul 16.

PMID:
22797060
2.

LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells.

Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, Goldsmith PK, Merino M, Kelly K.

Cancer Res. 2011 Dec 1;71(23):7301-11. doi: 10.1158/0008-5472.CAN-11-2381. Epub 2011 Oct 6.

3.

Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.

Park SJ, Lee KP, Kang S, Chung HY, Bae YS, Okajima F, Im DS.

Cell Signal. 2013 Nov;25(11):2147-54. doi: 10.1016/j.cellsig.2013.07.001. Epub 2013 Jul 6.

PMID:
23838008
4.

Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Zhu X, Zhao L, Park JW, Willingham MC, Cheng SY.

Neoplasia. 2014 Sep;16(9):757-69. doi: 10.1016/j.neo.2014.08.003.

5.

PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Guigon CJ, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2009 Jan 29;28(4):509-17. doi: 10.1038/onc.2008.407. Epub 2008 Nov 10.

6.

CD97: a dedifferentiation marker in human thyroid carcinomas.

Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O, Scherbaum WA, Dralle H, Hoang-Vu C.

Cancer Res. 1997 May 1;57(9):1798-806.

7.

TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor.

Xu J, Lai YJ, Lin WC, Lin FT.

J Biol Chem. 2004 Mar 12;279(11):10459-68. Epub 2003 Dec 18.

8.

The MLK-related kinase (MRK) is a novel RhoC effector that mediates lysophosphatidic acid (LPA)-stimulated tumor cell invasion.

Korkina O, Dong Z, Marullo A, Warshaw G, Symons M, Ruggieri R.

J Biol Chem. 2013 Feb 22;288(8):5364-73. doi: 10.1074/jbc.M112.414060. Epub 2013 Jan 14.

9.

MAGI-3 regulates LPA-induced activation of Erk and RhoA.

Zhang H, Wang D, Sun H, Hall RA, Yun CC.

Cell Signal. 2007 Feb;19(2):261-8. Epub 2006 Aug 9.

10.
11.

Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.

Furuya F, Lu C, Willingham MC, Cheng SY.

Carcinogenesis. 2007 Dec;28(12):2451-8. Epub 2007 Jul 28.

12.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

13.

Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model.

Kim DW, Walker RL, Meltzer PS, Cheng SY.

Carcinogenesis. 2013 Oct;34(10):2389-400. doi: 10.1093/carcin/bgt175. Epub 2013 May 22.

14.

Regulation of CD97 protein in thyroid carcinoma.

Hoang-Vu C, Bull K, Schwarz I, Krause G, Schmutzler C, Aust G, Köhrle J, Dralle H.

J Clin Endocrinol Metab. 1999 Mar;84(3):1104-9.

PMID:
10084602
15.

Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.

David M, Sahay D, Mege F, Descotes F, Leblanc R, Ribeiro J, Clézardin P, Peyruchaud O.

PLoS One. 2014 May 14;9(5):e97771. doi: 10.1371/journal.pone.0097771. eCollection 2014.

16.

Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues.

Steinert M, Wobus M, Boltze C, Schütz A, Wahlbuhl M, Hamann J, Aust G.

Am J Pathol. 2002 Nov;161(5):1657-67.

17.

Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.

Lu C, Zhu X, Willingham MC, Cheng SY.

Oncogene. 2012 Apr 19;31(16):2007-16. doi: 10.1038/onc.2011.390. Epub 2011 Sep 12.

18.

Shear stress-dependent downregulation of the adhesion-G protein-coupled receptor CD97 on circulating leukocytes upon contact with its ligand CD55.

Karpus ON, Veninga H, Hoek RM, Flierman D, van Buul JD, Vandenakker CC, vanBavel E, Medof ME, van Lier RA, Reedquist KA, Hamann J.

J Immunol. 2013 Apr 1;190(7):3740-8. doi: 10.4049/jimmunol.1202192. Epub 2013 Feb 27.

19.

Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling.

Ambesi A, McKeown-Longo PJ.

Mol Cancer Res. 2009 Feb;7(2):255-65. doi: 10.1158/1541-7786.MCR-08-0195. Epub 2009 Feb 10.

20.

Role of LPA4/p2y9/GPR23 in negative regulation of cell motility.

Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen CK, Fang X.

Mol Biol Cell. 2008 Dec;19(12):5435-45. doi: 10.1091/mbc.E08-03-0316. Epub 2008 Oct 8.

Items per page

Supplemental Content

Write to the Help Desk